The Response of Combined Chemotherapy with Nedaplatin and 5-FU for Recurrent and Advanced Esophageal Carcinoma -Comparison with Cisplatin/5-FU Combination Therapy

Satoru Ishibashi, Ryuzaburoh Shineha, Shukiti Miyazaki, Hideshi Yano, Takahiro Mori, Koh Sugawara, Goh Miyata, Susumu Satomi, Takashi Yoshioka^* and Ryunosuke Kanamaru^*

Division of Advanced Surgical Science and Technology, Graduated School of Medicine, Tohoku University, ^*Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University

We evaluated the response and toxicity of Nedaplatin, a new platinum analog, in patients with recurrent and advanced esophageal carcinoma, and compared with Cisplatin. Material and Method: Seven patients with organ recurrence after curative esophagectomy and 21 with nonresected advanced esophageal carcinoma (18 squamous cell, 3 undifferentiated) were treated with 1 to 6 courses of Nedaplatin combined with 5-FU. Nedaplatin (100 mg/m²) was administered intravenously on day 1 followed by continuous infusion of 5-FU (500 mg/m²) from days 1 to 5. Result: Response was 29.2% in cases of squamous cell carcinoma. By disease site, response was 57.1% for the liver including 2 CR cases, 50% for the lung and kidney, and 55.5% for the lymph node. In cases of undifferentiated carcinoma, response was 66.6%. Grade 3 and 4 thrombocytopenia were observed in 14.8% and leukocytopenia in 7.4%. Nausea and vomiting were observed in 28.6%, and 1 case dropped out due to severe vomitting. No toxic effects were observed in 28.4% of all cases. Conclusion: Combined chemotherapy with Nedaplatin and 5-FU is useful in treating organ and lymph node metastasis in esophageal carcinoma, and is more effective than Cisplatin/5-FU combination therapy in lymph node metastasis. Toxicity was well tolerated.

Key words
esophageal carcinoma, chemotherapy, nedaplatin, response, toxicity

Reprint requests
Satoru Ishibashi Division of Advanced Surgical Science and Technology, Graduated School of Medicine, Tohoku University

Accepted
April 25, 2001

To read the PDF file you will need Abobe Reader installed on your computer.